Johnson & Johnson (JNJ, Financial) saw a 10.3% growth in net sales as their Pharmaceutical segment–which represents 49% of overall sales–jumped 15% in the quarter. This has been due in part to the consistently growing sales of their lymphoma treatment, Imbruvica, increasing 46.7% year over year as additional implications continue to be approved by the FDA.
From Jeff Auxier (Trades, Portfolio)'s fourth quarter 2018 shareholder letter.
